Trial Profile
Special Use Investigation of HALAVEN (HAL03T) - Study on Safety and Efficacy in Patients With Soft Tissue Sarcomas
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 31 May 2022
Price :
$35
*
At a glance
- Drugs Eribulin (Primary)
- Indications Haemangiosarcoma; Leiomyosarcoma; Liposarcoma; Malignant fibrous histiocytoma; Rhabdomyosarcoma; Soft tissue sarcoma; Synovial sarcoma
- Focus Adverse reactions; Therapeutic Use
- Acronyms HAL03T
- Sponsors Eisai Co Ltd
- 11 May 2022 Results assessing safety and effectiveness of eribulin in Japanese patients with soft tissue sarcoma including rare subtypes published in the BMC Cancer
- 08 Mar 2019 Status changed from active, no longer recruiting to completed.
- 11 Dec 2018 Planned End Date changed from 1 Nov 2018 to 1 Jan 2019.